See the published version of this preprint at European Journal of Medical Research.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Fereshteh Ghiasvand
Tehran University of Medical Sciences
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: To assess the effectiveness of vitamin C treatment against coronavirus disease 2019 (COVID-19)
Methods: An open-label, randomized, and controlled trial was conducted on patients with severe COVID-19 infection. The case and control treatment groups each consisted of 30 patients. The control group received lopinavir/ritonavir and hydroxychloroquine and the case group received high-dose of vitamin C (six gr daily) added to the same regimen.
Results: There were no statistically significant differences between two groups with respect to age and gender, laboratory results, and underlying diseases. On the 3rd day of hospitalization, the mean core body temperatures was significantly lower and SpO2 was higher In the case group (p value = 0.001, and 0.014, respectively). The median length of hospitalization in case group which was significantly longer than the control group (8.5 days vs. 6.5 days) (p value = 0.0280). There was no significant difference in SpO2 levels at discharge time, the length of ICU stay, and mortality between the two groups.
Conclusions: We did not find significantly better outcomes in the group who were treated with high-dose vitamin C in addition to the main treatment regimen at discharge.
Trial registration: The project was registered by Iranian Registry of Clinical Trials.
IRCT20200411047025N1
Keywords
COVID-19, SARS-COV-2, 2019-nCoV, Vitamin C, Pneumonia, Hydroxychloroquine, Lopinavir, Ritonavir
Figure 1
Figure 2
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at European Journal of Medical Research.
Version 1
Posted 08 Jan, 2021
No community comments so far
Review #1 received
Received 08 Jan, 2021
Editorial decision: Minor revision
On 08 Jan, 2021
Review #2 received
Received 03 Jan, 2021
Reviewer #2 agreed
On 02 Jan, 2021
Editor assigned
On 01 Jan, 2021
Reviewers invited
Invitations sent on 01 Jan, 2021
Reviewer #1 agreed
On 01 Jan, 2021
Submission checks complete
On 01 Jan, 2021
Editor invited
On 01 Jan, 2021
First submitted
On 31 Dec, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
See the published version of this preprint at European Journal of Medical Research.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Fereshteh Ghiasvand
Tehran University of Medical Sciences
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at European Journal of Medical Research.
Version 1
Posted 08 Jan, 2021
No community comments so far
Review #1 received
Received 08 Jan, 2021
Editorial decision: Minor revision
On 08 Jan, 2021
Review #2 received
Received 03 Jan, 2021
Reviewer #2 agreed
On 02 Jan, 2021
Editor assigned
On 01 Jan, 2021
Reviewers invited
Invitations sent on 01 Jan, 2021
Reviewer #1 agreed
On 01 Jan, 2021
Submission checks complete
On 01 Jan, 2021
Editor invited
On 01 Jan, 2021
First submitted
On 31 Dec, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at European Journal of Medical Research.
Background: To assess the effectiveness of vitamin C treatment against coronavirus disease 2019 (COVID-19)
Methods: An open-label, randomized, and controlled trial was conducted on patients with severe COVID-19 infection. The case and control treatment groups each consisted of 30 patients. The control group received lopinavir/ritonavir and hydroxychloroquine and the case group received high-dose of vitamin C (six gr daily) added to the same regimen.
Results: There were no statistically significant differences between two groups with respect to age and gender, laboratory results, and underlying diseases. On the 3rd day of hospitalization, the mean core body temperatures was significantly lower and SpO2 was higher In the case group (p value = 0.001, and 0.014, respectively). The median length of hospitalization in case group which was significantly longer than the control group (8.5 days vs. 6.5 days) (p value = 0.0280). There was no significant difference in SpO2 levels at discharge time, the length of ICU stay, and mortality between the two groups.
Conclusions: We did not find significantly better outcomes in the group who were treated with high-dose vitamin C in addition to the main treatment regimen at discharge.
Trial registration: The project was registered by Iranian Registry of Clinical Trials.
IRCT20200411047025N1
Figure 1
Figure 2
Loading...